Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused corona virus disease 2019 (COVID-19) pandemic and led to mass casualty. Even though much effort has been put into development of vaccine and treatment methods to combat COVID-19, no safe and efficient cure has been discovered. Drug repurposing or drug repositioning which is a process of investigating pre-existing drug candidates for novel applications outside their original medical indication can speed up the drug development process. Raloxifene is a selective estrogen receptor modulator (SERM) that has been approved by FDA in 1997 for treatment and prevention of postmenopausal osteoporosis and cancer. Recently, raloxifene demonstrates efficacy in treating viral infections by Ebola, influenza A, and hepatitis C viruses and shows potential for drug repurposing for the treatment of SARS-CoV-2 infection. This review will provide an overview of raloxifene’s mechanism of action as a SERM and present proposed mechanisms of action in treatment of viral infections.
Article PDF
Similar content being viewed by others
References
Beral, V. and Million Women Study Collaborators. 2003. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362, 419–427.
Bryant, H.U., Glasebrook, A.L., Yang, N.N., and Sato, M. 1996. A pharmacological review of raloxifene. J. Bone Miner. Metab. 14, 1–9.
Brzozowski, A.M., Pike, A.C., Dauter, Z., Hubbard, R.E., Bonn, T., Engström, O., Öhman, L., Greene, G.L., Gustafsson, J.A., and Carlquist, M. 1997. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389, 753–758.
Cappuccio, F.P. and Siani, A. 2020. Covid-19 and cardiovascular risk: Susceptibility to infection to SARS-CoV-2, severity and prognosis of Covid-19 and blockade of the renin-angiotensin-aldosterone system. An evidence-based viewpoint. Nutr. Metab. Cardiovasc. Dis. 30, 1227–1235.
Clemett, D. and Spencer, C.M. 2000. Raloxifene: a review of its use in postmenopausal osteoporosis. Drugs 60, 379–411.
Coccolini, F., Sartelli, M., Kluger, Y., Pikoulis, E., Karamagioli, E., Moore, E.E., Biffl, W.L., Peitzman, A., Hecker, A., Chirica, M., et al. 2020. COVID-19 the showdown for mass casualty preparedness and management: the Cassandra Syndrome. World J. Emerg. Surg. 15, 26.
Collaborative Group on Hormonal Factors in Breast Cancer. 2019. Type and timing of menopausal hormone therapy and breast cancer risk: Individual participant meta-analysis of the worldwide epidemiological evidence. Lancet 394, 1159–1168.
Cummings, S.R., Eckert, S., Krueger, K.A., Grady, D., Powles, T.J., Cauley, J.A., Norton, L., Nickelsen, T., Bjarnason, N.H., Morrow, M., et al. 1999. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA 281, 2189–2197.
Dariya, B. and Nagaraju, G.P. 2020. Understanding novel COVID-19: Its impact on organ failure and risk assessment for diabetic and cancer patients. Cytokine Growth Factor Rev. 53, 43–52.
Delmas, P.D., Bjarnason, N.H., Mitlak, B.H., Ravoux, A.C., Shah, A.S., Huster, W.J., Draper, M., and Christiansen, C. 1997. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N. Engl. J. Med. 337, 1641–1647.
Delmas, P.D., Genant, H.K., Crans, G.G., Stock, J.L., Wong, M., Siris, E., and Adachi, J.D. 2003. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: Results from the MORE trial. Bone 33, 522–532.
DeMichele, A., Troxel, A.B., Berlin, J.A., Weber, A.L., Bunin, G.R., Turzo, E., Schinnar, R., Burgh, D., Berlin, M., Rubin, S.C., et al. 2008. Impact of raloxifene or tamoxifen use on endometrial cancer risk: a population-based case-control study. J. Clin. Oncol. 26, 4151–4159.
Di Martino, V., Lebray, P., Myers, R.P., Pannier, E., Paradis, V., Charlotte, F., Moussalli, J., Thabut, D., Buffet, C., and Poynard, T. 2004. Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure. Hepatology 40, 1426–1433.
Ettinger, B., Black, D.M., Mitlak, B.H., Knickerbocker, R.K., Nickelsen, T., Genant, H.K., Christiansen, C., Delmas, P.D., Zanchetta, J.R., Stakkestad, J., et al. 1999. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282, 637–645.
Evans, G.L., Bryant, H.U., Magee, D.E., and Turner, R.T. 1996. Raloxifene inhibits bone turnover and prevents further cancellous bone loss in adult ovariectomized rats with established osteopenia. Endocrinology 137, 4139–4144.
Fan, H., Du, X., Zhang, J., Zheng, H., Lu, X., Wu, Q., Li, H., Wang, H., Shi, Y., Gao, G., et al. 2017. Selective inhibition of Ebola entry with selective estrogen receptor modulators by disrupting the endolysosomal calcium. Sci. Rep. 7, 41226.
Fugère, P., Scheele, W.H., Shah, A., Strack, T.R., Glant, M.D., and Jolly, E. 2000. Uterine effects of raloxifene in comparison with continuous-combined hormone replacement therapy in post-menopausal women. Am. J. Obstet. Gynecol. 182, 568–574.
Furusyo, N., Ogawa, E., Sudoh, M., Murata, M., Ihara, T., Hayashi, T., Ikezaki, H., Hiramine, S., Mukae, H., Toyoda, K., et al. 2012. Raloxifene hydrochloride is an adjuvant antiviral treatment of postmenopausal women with chronic hepatitis C: a randomized trial. J. Hepatol. 57, 1186–1192.
Gavriatopoulou, M., Korompoki, E., Fotiou, D., Ntanasis-Stathopoulos, I., Psaltopoulou, T., Kastritis, E., Terpos, E., and Dimopoulos, M.A. 2020. Organ-specific manifestations of COVID-19 infection. Clin. Exp. Med. 20, 493–506.
Gianni, W., Ricci, A., Gazzaniga, P., Brama, M., Pietropaolo, M., Votano, S., Patanè, F., Aglianò, A.M., Spera, G., Marigliano, V., et al. 2004. Raloxifene modulates interleukin-6 and tumor necrosis factor-α synthesis in vivo: results from a pilot clinical study. J. Clin. Endocrinol. Metab. 89, 6097–6099.
Goldstein, S.R., Scheele, W.H., Rajagopalan, S.K., Wilkie, J.L., Walsh, B.W., and Parsons, A.K. 2000. A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium. Obstet. Gynecol. 95, 95–103.
Gottardis, M.M. and Jordan, V.C. 1987. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res. 47, 4020–4024.
Haldosén, L.A., Zhao, C., and Dahlman-Wright, K. 2014. Estrogen receptor beta in breast cancer. Mol. Cell. Endocrinol. 382, 665–672.
Heldring, N., Pike, A., Andersson, S., Matthews, J., Cheng, G., Hartman, J., Tujague, M., Ström, A., Treuter, E., Warner, M., et al. 2007. Estrogen receptors: how do they signal and what are their targets. Physiol. Rev. 87, 905–931.
Hoenen, T., Groseth, A., and Feldmann, H. 2019. Therapeutic strategies to target the Ebola virus life cycle. Nat. Rev. Microbiol. 17, 593–606.
Jones, J.E., Le Sage, V., and Lakdawala, S.S. 2020. Viral and host heterogeneity and their effects on the viral life cycle. Nat. Rev. Microbiol.https://doi.org/10.1038/s41579-020-00449-9.
Jordan, V.C. 2008. Tamoxifen: catalyst for the change to targeted therapy. Eur. J. Cancer 44, 30–38.
Jordan, R.E. and Adab, P. 2020. Who is most likely to be infected with SARS-CoV-2? Lancet Infect. Dis. 20, 995–996.
Kesharwani, D., Paliwal, R., Satapathy, T., and Das Paul, S. 2019. Rheumatiod arthritis: an updated overview of latest therapy and drug delivery. J. Pharmacopuncture 22, 210–224.
Kumar, V. and Chambon, P. 1988. The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer. Cell 55, 145–156.
Kumar, R., Zakharov, M.N., Khan, S.H., Miki, R., Jang, H., Toraldo, G., Singh, R., Bhasin, S., and Jasuja, R. 2011. The dynamic structure of the estrogen receptor. J. Amino Acids 2011, 812540.
Ledford, H. 2020. Coronavirus breakthrough: Dexamethasone is first drug shown to save lives. Nature 582, 469.
Levenson, A.S., Wolf, D.M., Catherino, W.H., Takei, H., and Jordan, V.C. 1998. Understanding the antiestrogenic actions of raloxifene and a mechanism of drug resistance to tamoxifen. Breast Cancer 5, 99–106.
Lippman, S.M. and Brown, P.H. 1999. Tamoxifen prevention of breast cancer: an instance of the fingerpost. J. Natl. Cancer Inst. 91, 1809–1819.
Lo, M.K., Albariño, C.G., Perry, J.K., Chang, S., Tchesnokov, E.P., Guerrero, L., Chakrabarti, A., Shrivastava-Ranjan, P., Chatterjee, P., McMullan, L.K., et al. 2020. Remdesivir targets a structurally analogous region of the Ebola virus and SARS-CoV-2 polymerases. Proc. Natl. Acad. Sci. USA 117, 26946–26954.
MacGregor, J.I. and Jordan, V.C. 1998. Basic guide to the mechanisms of antiestrogen action. Pharmacol. Rev. 50, 151–196.
Mahase, E. 2020. Covid-19: US approves remdesivir despite WHO trial showing lack of efficacy. BMJ 371, m4120.
Matthay, M.A. and Wick, K.D. 2020. Corticosteroids, COVID-19 pneumonia, and acute respiratory distress syndrome. J. Clin. Invest. 130, 6218–6221.
Myers, L., Balakrishnan, S., Reddy, S., and Gholamrezanezhad, A. 2020. Coronavirus outbreak: is radiology ready? Mass casualty incident planning. J. Am. Coll. Radiol. 17, 724–729.
Nelson, H.D. 2008. Menopause. Lancet 371, 760–770.
Omoto, Y. and Iwase, H. 2015. Clinical significance of estrogen receptor β in breast and prostate cancer from biological aspects. Cancer Sci. 106, 337–343.
Ozma, M.A., Maroufi, P., Khodadadi, E., Kose, S., Esposito, I., Ganbarov, K., Dao, S., Esposito, S., Dal, T., Zeinalzadeh, E., et al. 2020. Clinical manifestation, diagnosis, prevention and control of SARS-CoV-2 (COVID-19) during the outbreak period. Infez. Med. 28, 153–165.
Pardo, J., Shukla, A.M., Chamarthi, G., and Gupte, A. 2020. The journey of remdesivir: from Ebola to COVID-19. Drugs Context 9, 2020–4-14.
Patel, H.K. and Bihani, T. 2018. Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment. Pharmacol. Ther. 186, 1–24.
Patel, S.K., Saikumar, G., Rana, J., Dhama, J., Yatoo, M.I., Tiwari, R., Rodriguez-Morales, A.J., and Dhama, K. 2020. Dexamethasone: A boon for critically ill COVID-19 patients?. Travel Med. Infect. Dis. 37, 101844.
Pawlak, M., Lefebvre, P., and Staels, B. 2012. General molecular biology and architecture of nuclear receptors. Curr. Top. Med. Chem. 12, 486–504.
Pearce, S.T. and Jordan, V.C. 2004. The biological role of estrogen receptors a and β in cancer. Crit. Rev. Oncol. Hematol. 50, 3–22.
Peretz, J., Hall, O.J., and Klein, S.L. 2015. Sex differences in influenza virus infection, vaccination, and therapies. In Klein, S.L. and Roberts, C.W. (eds.), Sex and Gender Differences in Infection and Treatments for Infectious Diseases, pp. 183–210. Springer International Publishing, Cham, Switzerland.
Peretz, J., Pekosz, A., Lane, A.P., and Klein, S.L. 2016. Estrogenic compounds reduce influenza A virus replication in primary human nasal epithelial cells derived from female, but not male, donors. Am. J. Physiol. Lung Cell. Mol. Physiol. 310, L415–L425.
Perou, C.M., Sørlie, T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S., Rees, C.A., Pollack, J.R., Ross, D.T., Johnsen, H., Akslen, L.A., et al. 2000. Molecular portraits of human breast tumours. Nature 406, 747–752.
Prasad, A. and Prasad, M. 2020. Single virus targeting multiple organs: what we know and where we are heading?. Front. Med. 7, 370.
Ragia, G. and Manolopoulos, V.G. 2020. Inhibition of SARS-CoV-2 entry through the ACE2/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies. Eur. J. Clin. Pharmacol. 76, 1623–1630.
Rey, J.R.C., Cervino, E.V., Rentero, M.L., Crespo, E.C., Álvaro, A.O., and Casillas, M. 2009. Raloxifene: mechanism of action, effects on bone tissue, and applicability in clinical traumatology practice. Open Orthop. J. 3, 14–21.
Rhen, T. and Cidlowski, J.A. 2005. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N. Engl. J. Med. 353, 1711–1723.
Riggs, B.L. 2000. The mechanisms of estrogen regulation of bone resorption. J. Clin. Invest. 106, 1203–1204.
Riggs, B.L. and Hartmann, L.C. 2003. Selective estrogen-receptor modulators — mechanisms of action and application to clinical practice. N. Engl. J. Med. 348, 618–629.
Shimizu, I. 2003. Impact of oestrogens on the progression of liver disease. Liver Int. 23, 63–69.
Smetana, K.Jr., Rosel, D., and BrÁbek, J. 2020. Raloxifene and bazedoxifene could be promising candidates for preventing the COVID-19 related cytokine storm, ARDS and mortality. In Vivo 34, 3027–3028.
Straub, R.H. 2007. The complex role of estrogens in inflammation. Endocr. Rev. 28, 521–574.
Takeda, M., Ikeda, M., Mori, K., Yano, M., Ariumi, Y., Dansako, H., Wakita, T., and Kato, N. 2012. Raloxifene inhibits hepatitis C virus infection and replication. FEBS Open Bio. 2, 279–283.
Turner, C.H., Sato, M., and Bryant, H.U. 1994. Raloxifene preserves bone strength and bone mass in ovariectomized rats. Endocrinology 135, 2001–2005.
Tzukerman, M.T., Esty, A., Santiso-Mere, D., Danielian, P., Parker, M.G., Stein, R.B., Pike, J.W., and McDonnell, D.P. 1994. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol. Endocrinol. 8, 21–30.
Vogel, V.G., Costantino, J.P., Wickerham, D.L., Cronin, W.M., Cecchini, R.S., Atkins, J.N., Bevers, T.B., Fehrenbacher, L., Pajon, E.R Jr., Wade, J.L.3rd, et al. 2006. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of tamoxifen and raloxifene (STAR) p-2 trial. JAMA 295, 2727–2741.
WHO, World Health Organization. 2020. COVID-19 weekly epidemiological update, 17 November 2020. https://www.who.int/publications/m/item/weekly-epidemiological-update—-17-november-2020.
Yang, N.N., Venugopalan, M., Hardikar, S., and Glasebrook, A. 1996. Identification of an estrogen response element activated by metabolites of 17β-estradiol and raloxifene. Science 273, 1222–1225.
Yoon, Y.S., Jang, Y., Hoenen, T., Shin, H., Lee, Y., and Kim, M. 2020. Antiviral activity of sertindole, raloxifene and ibutamoren against transcription and replication-competent Ebola virus-like particles. BMB Rep. 53, 166–171.
Zhang, Y., Geng, X., Tan, Y., Li, Q., Xu, C., Xu, J., Hao, L., Zeng, Z., Luo, X., Liu, F., et al. 2020. New understanding of the damage of SARS-CoV-2 infection outside the respiratory system. Biomed. Pharmacother. 127, 110195.
Acknowledgments
This work has been supported by Korea Disease Control and Prevention Agency (KCDC 2020-ER5329-00).
Author information
Authors and Affiliations
Corresponding authors
Additional information
Conflict of Interest
We have no conflicts of interest to report.
Rights and permissions
About this article
Cite this article
Hong, S., Chang, J., Jeong, K. et al. Raloxifene as a treatment option for viral infections. J Microbiol. 59, 124–131 (2021). https://doi.org/10.1007/s12275-021-0617-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12275-021-0617-7